Anna Pellattiero

Employment

• Dana-Farber Cancer Institute Postdoctoral Fellow
  2025 - Present
• University of Padua Postdoctoral Fellow
  2019 - 2025

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (8)

• Small molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia
  Science Advances 2025 DOI: 10.1126/sciadv.adx8662
  +Save
• Metastatic breast cancer cells are selectively dependent on the mitochondrial cristae-shaping protein OPA1
  Cell Death & Disease 2025 DOI: 10.1038/s41419-025-07878-5
  +Save
• Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors
  Science Advances 2025 DOI: 10.1126/sciadv.adx4562
  +Save
• Inhibition of the mitochondria-shaping protein Opa1 restores sensitivity to Gefitinib in a lung adenocarcinomaresistant cell line
  Cell Death & Disease 2023 DOI: 10.1038/s41419-023-05768-2
  +Save
• Oxidization of optic atrophy 1 cysteines occurs during heart ischemia-reperfusion and amplifies cell death by oxidative stress
  Redox Biology 2023 DOI: 10.1016/j.redox.2023.102755
  +Save
• Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1
  Cell Metabolism 2020 DOI: 10.1016/j.cmet.2020.04.007
  +Save
• Flaming Mitochondria: The Anti-inflammatory Drug Leflunomide Boosts Mitofusins
  Cell Chemical Biology 2018 DOI: 10.1016/j.chembiol.2018.02.014
  +Save
• The cristae modulator Optic atrophy 1 requires mitochondrial ATP synthase oligomers to safeguard mitochondrial function
  Nature Communications 2018 DOI: 10.1038/s41467-018-05655-x
  +Save